文献速递免疫规划传染病防控与疫情报告

先进氧化技术用于下一代灭活西尼罗病毒疫苗开发

Advanced oxidation technology for the development of a next-generation inactivated West Nile virus vaccine.
PubMed 文献 · Vaccine · 2018-12-31

西尼罗病毒(WNV)在美国大陆是最常见的蚊媒疾病,目前尚无获批人用疫苗。研究描述一种下一代氧化灭活方法(HydroVax-II),利用低浓度过氧化氢联合铜离子与美替沙腙,并添加低比例甲醛,快速灭活病毒并更好保留WNV包膜蛋白三个结构域的中和表位。该技术结合改良制造工艺,使疫苗诱导的WNV特异性中和抗体反应比第一代纯过氧化氢疫苗高130倍,并提供100%针对致死性WNV感染的保护。

要点

  • HydroVax-II采用低浓度H2O2联合铜离子/美替沙腙及低比例甲醛的双重灭活策略。
  • 该技术快速灭活WNV并更好保留包膜蛋白三个结构域的中和表位。
  • 疫苗诱导的中和抗体反应较第一代H2O2-only疫苗高130倍,提供100%致死攻击保护。

核心结论

  • HydroVax-II先进氧化灭活技术可快速灭活WNV并更好保留中和表位,诱导的中和抗体反应较第一代H2O2-only疫苗高130倍,提供100%针对致死性WNV感染的保护。

研究设计与样本

  • 本文描述下一代氧化灭活方法(HydroVax-II)的临床前开发,未报告人体临床试验设计或样本量。

主要发现

  • HydroVax-II结合低浓度H2O2、铜离子与美替沙腙及低比例甲醛,实现快速病毒灭活并大幅改善WNV包膜蛋白三个结构域中和表位的保留。
  • 结合更精细的制造技术,该灭活技术使疫苗介导的WNV特异性中和抗体反应比第一代纯H2O2疫苗高130倍。
  • 该疫苗提供100%针对致死性WNV感染的保护。

关键数值与推荐

  • 第一代HydroVax(3% H2O2灭活)在I期临床试验中安全且具适度免疫原性。
  • HydroVax-II诱导的WNV特异性中和抗体反应较第一代H2O2-only疫苗高130倍。
  • HydroVax-II提供100%针对致死性WNV感染的保护。

临床怎么用

  • 该技术尚处临床前开发阶段,暂未提供人用临床使用建议。

局限性

  • 原文未报告研究样本量、统计显著性及人体临床数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

West Nile virus (WNV) is the most frequent mosquito-borne disease reported in the continental United States and although an effective veterinary vaccine exists for horses, there is still no commercial vaccine approved for human use. We have previously tested a 3% hydrogen peroxide (H2O2)-based WNV inactivation approach termed, HydroVax, in Phase I clinical trials and the vaccine was found to be safe and modestly immunogenic. Here, we describe an advanced, next-generation oxidation approach (HydroVax-II) for the development of inactivated vaccines that utilizes reduced concentrations of H2O2 in combination with copper (cupric ions, Cu2+) complexed with the antiviral compound, methisazone (MZ). Further enhancement of this oxidative approach included the addition of a low percentage of formaldehyde, a cross-linking reagent with a different mechanism of action that, together with H2O2/Cu/MZ, provides a robust two-pronged approach to virus inactivation. Together, this new approach results in rapid virus inactivation while greatly improving the maintenance of WNV-specific neutralizing epitopes mapped across the three structural domains of the WNV envelope protein. In combination with more refined manufacturing techniques, this inactivation technology resulted in vaccine-mediated WNV-specific neutralizing antibody responses that were 130-fold higher than that observed using the first generation, H2O2-only vaccine approach and provided 100% protection against lethal WNV infection. This new approach to vaccine development represents an important area for future investigation with the potential not only for improving vaccines against WNV, but other clinically relevant viruses as well.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Quintel BK, Thomas A, Poer DeRaad DE, et al. Advanced oxidation technology for the development of a next-generation inactivated West Nile virus vaccine. Vaccine. 2018. PMID: 30606462. doi:10.1016/j.vaccine.2018.12.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。